Mara Goldstein
Stock Analyst at Mizuho
(2.59)
# 2,046
Out of 5,169 analysts
70
Total ratings
48.08%
Success rate
14.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Maintains: Outperform | $410 → $600 | $23.65 | +2,437.00% | 2 | Jan 27, 2026 | |
| KURA Kura Oncology | Maintains: Outperform | $32 → $30 | $8.39 | +257.57% | 3 | May 19, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $30 → $10 | $3.77 | +165.25% | 5 | May 12, 2025 | |
| VSTM Verastem | Maintains: Outperform | $9 → $8 | $5.56 | +43.88% | 7 | Apr 9, 2025 | |
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $22.21 | +89.10% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $11.59 | +331.41% | 2 | Jan 22, 2024 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $92.24 | -16.52% | 5 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $13.50 | -48.15% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $1.06 | +654.72% | 5 | Nov 20, 2023 | |
| NKTR Nektar Therapeutics | Reiterates: Neutral | $90 | $73.18 | +22.98% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.5 | $14.08 | -75.14% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $1.84 | +19,465.22% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 → $20 | $4.78 | +318.41% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $130 | $114.50 | +13.54% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $4.40 | -54.55% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $1.45 | +727.59% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 → $20 | $62.19 | -67.84% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $48 | $6.86 | +599.71% | 5 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $28.54 | - | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $5.55 | +152.25% | 1 | Oct 12, 2017 |
Syndax Pharmaceuticals
Jan 27, 2026
Maintains: Outperform
Price Target: $410 → $600
Current: $23.65
Upside: +2,437.00%
Kura Oncology
May 19, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $8.39
Upside: +257.57%
Iovance Biotherapeutics
May 12, 2025
Maintains: Outperform
Price Target: $30 → $10
Current: $3.77
Upside: +165.25%
Verastem
Apr 9, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $5.56
Upside: +43.88%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $22.21
Upside: +89.10%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $11.59
Upside: +331.41%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $92.24
Upside: -16.52%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $13.50
Upside: -48.15%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $1.06
Upside: +654.72%
Nektar Therapeutics
Aug 7, 2023
Reiterates: Neutral
Price Target: $90
Current: $73.18
Upside: +22.98%
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $14.08
Upside: -75.14%
Apr 24, 2023
Reiterates: Buy
Price Target: $360
Current: $1.84
Upside: +19,465.22%
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $4.78
Upside: +318.41%
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $114.50
Upside: +13.54%
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $4.40
Upside: -54.55%
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $1.45
Upside: +727.59%
Sep 6, 2019
Reiterates: Overweight
Price Target: $14 → $20
Current: $62.19
Upside: -67.84%
Jul 8, 2019
Downgrades: Neutral
Price Target: $34 → $48
Current: $6.86
Upside: +599.71%
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $28.54
Upside: -
Oct 12, 2017
Maintains: Overweight
Price Target: $12 → $14
Current: $5.55
Upside: +152.25%